{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:50:39Z","timestamp":1791654639901,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Co., Ltd. In March 2019"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD)\/pneumonitis is an important adverse drug reaction associated with trastuzumab deruxtecan (T-DXd). This report comprehensively characterized clinical and imaging features of T-DXd-related ILD, systematically evaluated by an independent ILD Adjudication Committee (AC), in Japanese patients with breast\/gastric cancer from all-patient post-marketing surveillance studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This post hoc analysis evaluated independent ILD AC-adjudicated T-DXd-related ILD cases. Demographics, clinical\/radiological features, time to onset, treatment interventions, and outcomes (followed up to 12\u2009months from onset) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2801\u2009T-DXd-treated patients (breast cancer: 1731; gastric cancer: 1070), 421 potential cases were reviewed: 381 were adjudicated as T-DXd-related ILD (breast cancer: 278; gastric cancer: 103). Median age was 65.0\u2009years, 75.1% were female, and 28.3% had a smoking history. ILD occurred throughout observation (including fatal cases \u226512\u2009months post-initiation) with no specific onset window. Time to onset did not differ across CTCAE grades. Organizing pneumonia was the predominant imaging pattern (67.7%), followed by hypersensitivity pneumonitis (14.2%) and diffuse alveolar damage (DAD, 12.6%). Most cases (78.2%) were worst CTCAE Grade 1-2. Grade 5 ILD occurred in 30 patients (7.9%), with DAD the most common pattern (26 patients). Overall recovery was 83.5%. Corticosteroids were used in 54.6% of cases, with 79.3% responding. High-dose corticosteroids and additional immunosuppressants were ineffective in seven DAD cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most T-DXd-related ILD cases were mild\/moderate and corticosteroid-responsive; DAD pattern was associated with higher mortality. These findings underscore the importance of vigilant monitoring, early recognition, and prompt corticosteroid treatment to mitigate fatal T-DXd-related ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag340","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:30:26Z","timestamp":1788521426000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-0800","authenticated-orcid":false,"given":"Yutaka","family":"Fujiwara","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, Aichi Cancer Center Hospital , Aichi, 464-8681,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Oikado","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Toranomon Hospital , Tokyo, 105-8470,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center , Yokohama-shi, Kanagawa, 236-0051,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Imaging Center, Midtown Clinic East , Tokyo, 107-0052,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Juntendo University Urayasu Hospital , Urayasu-shi, Chiba, 279-0021,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Radiology, Shizuoka Cancer Center , Shizuoka, 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Center for Clinical Research and Trials, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo, 113-8677,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kyorin University Hospital , Tokyo, 181-8611,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nippon Medical School Musashi Kosugi Hospital , Kawasaki-shi, Kanagawa, 211-8533,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yagihashi","sequence":"additional","affiliation":[{"name":"Department of Radiology, St. Marianna University Yokohama Seibu Hospital , Yokohama-shi, Kanagawa, 241-0811,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kyowa Chuo Hospital , Chikusei-shi, Ibaraki, 309-1195,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Koto, Tokyo, 135-8550,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center , Shizuoka, 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Jikei University School of Medicine , Tokyo, 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8909-5709","authenticated-orcid":false,"given":"Teppei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Aichi Cancer Center Hospital , Aichi, 464-8681,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-5832","authenticated-orcid":false,"given":"Saiko","family":"Isshiki","sequence":"additional","affiliation":[{"name":"Department of Radiology, Niiza-Shiki Central General Hospital , Niiza-shi, Saitama, 352-0001,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakui","sequence":"additional","affiliation":[{"name":"Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo, 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center , Shizuoka, 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-7911","authenticated-orcid":false,"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital , Hirakata-shi, Osaka, 573-1191,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Juntendo University Graduate School of Medicine , Tokyo, 113-8421,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Medical University International Medical Center , Hidaka-shi, Saitama, 350-1298,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[{"name":"Breast Medical Oncology Department, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo, 135-8550,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, Esophageal Medical Oncology and Gastrointestinal Medical Oncology, National Cancer Center Hospital , Tokyo, 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Hiruma","sequence":"additional","affiliation":[{"name":"Department of Medical Safety, Daiichi Sankyo Co., Ltd. , Tokyo, 103-8426,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Medical Safety, Daiichi Sankyo Co., Ltd. , Tokyo, 103-8426,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Data Intelligence, Daiichi Sankyo Co., Ltd. , Tokyo, 140-8710,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Kuwano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, International University of Health and Welfare , Tokyo, 108-8329,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026101013471508100_oyag340-B1","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026101013471508100_oyag340-B2","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026101013471508100_oyag340-B3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101013471508100_oyag340-B4","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101013471508100_oyag340-B5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"2026101013471508100_oyag340-B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"2026101013471508100_oyag340-B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"2026101013471508100_oyag340-B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026101013471508100_oyag340-B9","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"2026101013471508100_oyag340-B10","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"2026101013471508100_oyag340-B11","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"2026101013471508100_oyag340-B12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026101013471508100_oyag340-B13","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026101013471508100_oyag340-B14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12282-025-01814-3","article-title":"Real-world analysis of interstitial lung disease\/pneumonitis in japanese patients with breast cancer receiving trastuzumab deruxtecan","volume":"33","author":"Tsurutani","year":"2026","journal-title":"Breast Cancer"},{"key":"2026101013471508100_oyag340-B15","doi-asserted-by":"publisher","first-page":"105914","DOI":"10.1016\/j.esmoop.2025.105914","article-title":"Real-world evaluation of interstitial lung disease\/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan","volume":"10","author":"Kawakami","year":"2025","journal-title":"ESMO Open"},{"key":"2026101013471508100_oyag340-B16","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10147-023-02414-x","article-title":"Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan","volume":"28","author":"Baba","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2026101013471508100_oyag340-B17","doi-asserted-by":"publisher","first-page":"e2300391","DOI":"10.1200\/PO.23.00391","article-title":"Trastuzumab deruxtecan\u2013related interstitial lung disease\/pneumonitis: computed tomography imaging patterns to guide diagnosis and management","volume":"7","author":"Nishino","year":"2023","journal-title":"JCO Precis Oncol."},{"key":"2026101013471508100_oyag340-B18","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"2026101013471508100_oyag340-B19","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis\u2014focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026101013471508100_oyag340-B20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.resinv.2025.04.015","article-title":"Clinical characteristics of drug-induced interstitial pneumonia in Japan","volume":"63","author":"Yamanaka","year":"2025","journal-title":"Respir Investig"},{"key":"2026101013471508100_oyag340-B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5152\/dir.2022.21614","article-title":"Drug-induced lung disease: a brief update for radiologists","volume":"29","author":"Ufuk","year":"2023","journal-title":"Diagn Interv Radiol"},{"key":"2026101013471508100_oyag340-B22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/diagnostics10040244","article-title":"HRCT patterns of drug-induced interstitial lung diseases: a review","volume":"10","author":"Distefano","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2026101013471508100_oyag340-B23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the fleischner society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"key":"2026101013471508100_oyag340-B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.lungcan.2006.02.002","article-title":"Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the west Japan thoracic oncology group","volume":"52","author":"Endo","year":"2006","journal-title":"Lung Cancer"},{"key":"2026101013471508100_oyag340-B25","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","article-title":"Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan","volume":"15","author":"Gemma","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026101013471508100_oyag340-B26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"key":"2026101013471508100_oyag340-B27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00005382-200310000-00004","article-title":"Methotrexate-induced pulmonary injury: serial CT findings","volume":"18","author":"Arakawa","year":"2003","journal-title":"J Thorac Imaging"},{"key":"2026101013471508100_oyag340-B28","doi-asserted-by":"publisher","first-page":"200463","DOI":"10.1148\/radiol.2020200463","article-title":"Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection","volume":"295","author":"Bernheim","year":"2020","journal-title":"Radiology"},{"key":"2026101013471508100_oyag340-B29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2214\/AJR.20.22976","article-title":"Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study","volume":"214","author":"Zhao","year":"2020","journal-title":"Am J Roentgenol"},{"key":"2026101013471508100_oyag340-B30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4329\/wjr.v6.i10.779","article-title":"Imaging of community-acquired pneumonia: roles of imaging examinations, imaging diagnosis of specific pathogens and discrimination from noninfectious diseases","volume":"6","author":"Nambu","year":"2014","journal-title":"World J Radiol"},{"key":"2026101013471508100_oyag340-B31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1148\/radiology.166.3.3340765","article-title":"Pulmonary lymphangitic carcinomatosis: CT and pathologic findings","volume":"166","author":"Munk","year":"1988","journal-title":"Radiology"},{"key":"2026101013471508100_oyag340-B32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4081\/monaldi.2023.2633","article-title":"Clinical characteristics for distinguishing between acute cardiogenic pulmonary edema and community-acquired pneumonia in elderly patients: a prospective observational study","volume":"94","author":"Inui","year":"2023","journal-title":"Monaldi Arch Chest Dis"},{"key":"2026101013471508100_oyag340-B33","doi-asserted-by":"publisher","first-page":"20200997","DOI":"10.1259\/bjr.20200997","article-title":"CT findings of acute radiation-induced pneumonitis in breast cancer","volume":"94","author":"Jung","year":"2021","journal-title":"Br J Radiol"},{"key":"2026101013471508100_oyag340-B34","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"2026101013471508100_oyag340-B35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.resinv.2014.11.001","article-title":"A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan","volume":"53","author":"Bando","year":"2015","journal-title":"Respir Investig"},{"key":"2026101013471508100_oyag340-B36","doi-asserted-by":"publisher","first-page":"e007409","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026101013471508100_oyag340-B37","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.chest.2025.11.005","article-title":"A 49-year-old woman with trastuzumab-deruxtecan-induced pneumonitis responsive to IV immunoglobulin therapy after failed steroid treatment","volume":"169","author":"Abbasi","year":"2026","journal-title":"Chest"},{"key":"2026101013471508100_oyag340-B38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.29011\/2574-7754.101433","article-title":"A reversible case of advanced interstitial lung disease in a patient with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan","volume":"8","author":"Costa","year":"2023","journal-title":"Ann Case Rep"},{"key":"2026101013471508100_oyag340-B39","doi-asserted-by":"publisher","first-page":"1567317","DOI":"10.3389\/fonc.2025.1567317","article-title":"Cyclophosphamide for anticancer therapy-induced interstitial lung disease in the modern era: a retrospective cohort study","volume":"15","author":"Katahara","year":"2025","journal-title":"Front Oncol"},{"key":"2026101013471508100_oyag340-B40","doi-asserted-by":"publisher","first-page":"1638194","DOI":"10.3389\/fonc.2025.1638194","article-title":"Cyclophosphamide for severe T-DXd-induced interstitial lung disease in low-HER2 breast cancer: a case report and mechanistic insights","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"2026101013471508100_oyag340-B41","doi-asserted-by":"publisher","first-page":"104128","DOI":"10.1016\/j.esmoop.2024.104128","article-title":"Treatment with infliximab and tacrolimus in steroid-refractory pneumonitis secondary to anti-HER2 therapy","volume":"10","author":"Fakih","year":"2025","journal-title":"ESMO Open"},{"key":"2026101013471508100_oyag340-B42","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1200\/OP.23.00097","article-title":"Detecting and managing T-DXd-related interstitial lung disease: the five \u201cS\u201d rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026101013471508100_oyag340-B43","doi-asserted-by":"publisher","first-page":"102043","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag340\/70984375\/oyag340.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag340\/70984375\/oyag340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag340\/70984375\/oyag340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:47:24Z","timestamp":1791654444000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag340\/8787395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag340","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,7]]},"article-number":"oyag340"}}